Dr. Sherman spent almost three decades at the FDA and held the principal deputy commissioner role — the most senior career position at the agency — from 2017 to early 2019. She has since launched her own consulting firm, Rachel Sherman Partners, to advise medical product makers through the development and regulation processes.
Sema4 spun out of New York City-based Mount Sinai Health System in 2017, building upon multiple genomics and data science initiatives launched within the health system’s department of genetics and genomic sciences and the Icahn Institute for Genomics and Multiscale Biology.
“Accelerating precision medicine is critical for public health, and I believe that Sema4 has the team, talent and a clearly demonstrated commitment to bring real value to patients,” Dr. Sherman said in a March 12 news release. “I am delighted to have the opportunity to work closely with the Sema4 team as they continue to deliver novel clinical insights in support of better patient outcomes in cancer and women’s health.”
Dr. Sherman is joined on the Sema4 board of directors by Kenneth Davis, MD, president and CEO of Mount Sinai Health System, and Dennis Charney, MD, dean of Mount Sinai’s Icahn School of Medicine, among several others.
More articles on data analytics:
Siemens Healthineers launches clinical decision support platform: 3 notes
Baystate Health innovation center testing AI-powered analytics platform
Genomics study lands Intermountain spot on most innovative biotech companies list
